Communications Third Time’s the Charm: Inc. 5000 Lists Us Again, Validates the Cadence Way of Doing Business By Sugata Biswas | Communications
For the 3rd Time, Women-Owned Cadence Communications & Research Appears on the Inc. 5000, Ranking No. 3160 With Three-Year Revenue Growth of 116% Cadence Communications & Research Ranked by Inc. Magazine as One of the Nation’s Fastest-Growing Private Companies
FEATURED INSIGHTSMedical CommunicationsOncology UpdatesWhite Papers White Paper: Immune Checkpoint Inhibitors for the Treatment of Cancer By Zachary Moore | FEATURED INSIGHTS, Medical Communications, Oncology Updates, White Papers
Approval BlogMedical CommunicationsOncology Updates Durvalumab receives FDA-approval as a consolidation treatment for Stage III NSCLC By Zachary Moore | Approval Blog, Medical Communications, Oncology Updates
Cadence Communications & Research Ranked by Inc. Magazine as One of the Nation’s Fastest-Growing Private Companies
Rucaparib for Maintenance Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Adcetris is Approved for the Frontline Treatment of stage III or IV Classical Hodgkin Lymphoma in Combination with Chemotherapy
Afatinib receives extended approval for frontline treatment of Patients with Non-resistant EGFR Mutation-positive NSCLC
Cadence expands its medical communication offerings through KOL Connect®, a comprehensive KOL relationship management solution
Why Cadence Achieved Status as One of Inc.’s Fastest-Growing Private Companies for Second Year in a Row!
